Search research articles
Contact Us
Filters
Showing results (31-40 of 130) with videos related to
Page
of 13
Sort By:
The Journal of Dermatological Treatment
|
August 26, 2022
Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
Bruce Strober, Dhaval Patil, Robert R McLean, et al.
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Samantha Goldburg, Rebecca Chen, Wayne Langholff, et al.
Frontiers in Medicine
|
May 30, 2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of <i>Prevotella histicola</i>, in adults with mild-to-moderate plaque psoriasis
Benjamin D Ehst, Bruce Strober, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology
|
August 13, 2011
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials
Craig Leonardi, Kim Papp, Bruce Strober, et al.
The Journal of Dermatological Treatment
|
December 5, 2025
Laboratory monitoring in patients with moderate to severe plaque psoriasis
Jonathan M Fenkel, John A Osborne, April W Armstrong, et al.
Journal of the American Academy of Dermatology
|
March 18, 2026
Reply to Woodie, et al., "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX."
Tiago Torres, Andrew Blauvelt, Bruce Strober, et al.
The Journal of Dermatological Treatment
|
December 11, 2023
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry
Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology
|
August 20, 2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Bruce Strober, Caitriona Ryan, Peter van de Kerkhof, et al.
Journal of the American Academy of Dermatology
|
January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Kim Papp, Alan Menter, Bruce Strober, et al.
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry
Mark G Lebwohl, Rose Anne Medeiros, Rachel H Mackey, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 130) with videos related to
Sort By:
Page
of 13
The Journal of Dermatological Treatment
|
August 26, 2022
Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
Bruce Strober, Dhaval Patil, Robert R McLean, et al.
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Samantha Goldburg, Rebecca Chen, Wayne Langholff, et al.
Frontiers in Medicine
|
May 30, 2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of <i>Prevotella histicola</i>, in adults with mild-to-moderate plaque psoriasis
Benjamin D Ehst, Bruce Strober, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology
|
August 13, 2011
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials
Craig Leonardi, Kim Papp, Bruce Strober, et al.
The Journal of Dermatological Treatment
|
December 5, 2025
Laboratory monitoring in patients with moderate to severe plaque psoriasis
Jonathan M Fenkel, John A Osborne, April W Armstrong, et al.
Journal of the American Academy of Dermatology
|
March 18, 2026
Reply to Woodie, et al., "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX."
Tiago Torres, Andrew Blauvelt, Bruce Strober, et al.
The Journal of Dermatological Treatment
|
December 11, 2023
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry
Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology
|
August 20, 2019
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Bruce Strober, Caitriona Ryan, Peter van de Kerkhof, et al.
Journal of the American Academy of Dermatology
|
January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Kim Papp, Alan Menter, Bruce Strober, et al.
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry
Mark G Lebwohl, Rose Anne Medeiros, Rachel H Mackey, et al.
Page
of 13